Insider · CIK 0001778307
Cheng Andrew
ceopresidentofficerdirector
Files at AKRO (Akero Therapeutics, Inc.). First filing Oct 18, 2024, latest Dec 12, 2024.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $7.4M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 53Moderate | sell 6 | AKRO Akero Therapeutics, Inc. | $242k | 7,855 | -1% | - | |
| 27Weak | sell 610b5-1 | AKRO Akero Therapeutics, Inc. | $802k | 25,000 | -4% | - | |
| 35Weak | sell 310b5-1 | AKRO Akero Therapeutics, Inc. | $3.4M | 108,366 | -16% | - | |
| 35Weak | sell 310b5-1 | AKRO Akero Therapeutics, Inc. | $2.9M | 91,634 | -15% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2024 | AKRO Akero Therapeutics, Inc. | AGrant or award Common Stock | +98,500 | $0.00 | $0 | 696,062 | Dec 18, 2024 |
| Dec 16, 2024 | AKRO Akero Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +295,600 | $0.00 | $0 | 295,600 | Dec 18, 2024 |
| Dec 10, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock | -7,855 | $30.79 | $242k | 597,562 | Dec 12, 2024 |
| Dec 2, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +25,000 | $21.10 | $528k | 630,417 | Dec 4, 2024 |
| Dec 2, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -25,000 | $32.09 | $802k | 605,417 | Dec 4, 2024 |
| Dec 2, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 111,029 | Dec 4, 2024 |
| Nov 1, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +81,280 | $21.10 | $1.7M | 686,697 | Nov 5, 2024 |
| Nov 1, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -81,280 | $31.47 | $2.6M | 605,417 | Nov 5, 2024 |
| Nov 1, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +27,086 | $21.10 | $572k | 632,503 | Nov 5, 2024 |
| Nov 1, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -27,086 | $32.50 | $880k | 605,417 | Nov 5, 2024 |
| Nov 1, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -81,280 | $0.00 | $0 | 163,115 | Nov 5, 2024 |
| Nov 1, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,086 | $0.00 | $0 | 136,029 | Nov 5, 2024 |
| Oct 16, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +24,992 | $21.10 | $527k | 630,409 | Oct 18, 2024 |
| Oct 16, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -24,992 | $31.14 | $778k | 605,417 | Oct 18, 2024 |
| Oct 17, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +3,103 | $21.10 | $65k | 608,520 | Oct 18, 2024 |
| Oct 17, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,103 | $31.12 | $97k | 605,417 | Oct 18, 2024 |
| Oct 18, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +63,539 | $21.10 | $1.3M | 668,956 | Oct 18, 2024 |
| Oct 18, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -63,313 | $31.53 | $2.0M | 605,643 | Oct 18, 2024 |
| Oct 18, 2024 | AKRO Akero Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -226 | $32.12 | $7,259 | 605,417 | Oct 18, 2024 |
| Oct 16, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -24,992 | $0.00 | $0 | 160,351 | Oct 18, 2024 |
| Oct 17, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -3,103 | $0.00 | $0 | 157,248 | Oct 18, 2024 |
| Oct 18, 2024 | AKRO Akero Therapeutics, Inc. | MOption exercise Stock Option (Righto Buy)derivative10b5-1 | -63,539 | $0.00 | $0 | 93,709 | Oct 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.